A Study of Erlotinib (Tarceva) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 18 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Dec 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 19 Feb 2013 Planned end date changed from 1 Jan 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.